Clovis Oncology, Inc. (NASDAQ: CLVS) reported the first set of data from the Phase 3 ARIEL4 study of Rebraca will take place in an oral presentation today at the Society of Gynecologic Oncology Virtual Annual Meeting on Woman’s Cancer. The data will show Rubraca significantly improving PFS compared to standard of care chemotherapy, including chemotherapy with patients diagnosed with relapsed ovarian cancer and a deleterious BRCA mutation who have had two or more prior lines of chemotherapy.
“Data from the ARIEL4 study meaningfully enhance our understanding about the role of Rubraca among women with BRCA mutation-positive relapsed ovarian cancer, as well as the clinical relevance of BRCA reversion mutations,” said Dr. Rebecca Kristeleit, Co-Coordinating Investigator of ARIEL4 and Consultant Medical Oncologist, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. “This is important because women with more advanced disease have fewer treatment options, and it is increasingly important to understand how specific mutations affect treatment outcomes.”
Data will be presented by Dr. Kristeleit during the SGO Scientific Plenary 1: Innovation and Progress in Gynecologic Oncology session from 2:35 pm - 3:45 pm CT. It may be viewed here at 2:35 pm CT